FRANCE BED HOLDINGS (7840) FY2027 Q1 Earnings Report

Quick View

Executive Summary

Q1 of the fiscal year ending March 2027 delivered strong results, with revenue growth accompanied by progress in absorbing SG&A expenses, resulting in earnings growth substantially exceeding the rate of revenue growth. Revenue was ¥14.97B (+4.2% YoY), Operating Income was ¥0.99B (+26.6%), Ordinary Income was ¥1.03B (+30.0%), and Net Income attributable to owners of the parent was ¥0.63B (+32.9%). The Operating Margin improved to 6.6% from approximately 5.5% in the same period of the previous year, with positive operating leverage driven by the high gross margin of 56.7% and restrained growth in SG&A expenses supporting the increase in earnings.

Factors Affecting Performance

【Revenue】Revenue was ¥14.97B, up +4.2% YoY. Both segments contributed to revenue growth: the core Medical Services segment generated ¥9.92B (+3.3%), while Interior Health generated ¥4.90B (+5.9%). Medical Services accounted for approximately 66% of the revenue mix and Interior Health approximately 33%, indicating that the core businesses are supporting overall growth.

【Profit and Loss】Operating Income of ¥0.99B (+26.6%), Ordinary Income of ¥1.03B (+30.0%), and Net Income of ¥0.63B (+32.9%) all grew faster than revenue. Segment profit, based on Ordinary Income, was ¥0.75B for Medical Services (+15.9%, profit margin 7.5%) and ¥0.30B for Interior Health (+73.1%, profit margin 6.2%). In particular, the improvement in Interior Health’s profit margin made a significant contribution to overall earnings growth. Extraordinary items were limited to extraordinary income of ¥0.002B, with no material impact, indicating low dependence on temporary factors. Non-operating income was ¥0.07B, primarily consisting of interest and dividend income, but remained limited at 0.4% of revenue. Overall, the company achieved higher revenue and earnings, representing high-quality earnings growth accompanied by margin improvement.

Segment Analysis

The reported segments are Medical Services and Interior Health. Medical Services is the core business, with revenue of ¥9.92B (+3.3%), segment profit of ¥0.75B (+15.9%), and a profit margin of 7.5%, accounting for approximately 71% of total reported segment profit. Interior Health recorded revenue of ¥4.90B (+5.9%), segment profit of ¥0.30B (+73.1%), and a profit margin of 6.2%, representing substantial earnings growth; however, the relatively low profit level in the same period of the previous year may also have amplified the growth rate. Both segments achieved higher revenue and earnings, contributing to improved operating leverage at the company-wide level.

Key Financial Indicators

【Profitability】The Operating Margin of 6.6% improved from approximately 5.5% in the same period of the previous year, while the Net Margin of 4.2% also increased from approximately 3.3%. The gross margin remained high at 56.7%, and the ability to absorb the 50.0% SG&A expense ratio was the primary driver of earnings growth.【Cash Flow Quality】Extraordinary income was limited to approximately 0.3% of Net Income, indicating that Q1 earnings consisted primarily of recurring operating profits.【Investment Efficiency】ROE on a cumulative basis was 1.6%, Basic EPS was ¥19.02 (+34.6% from ¥13.14), and BPS was ¥1,195.11. On an annualized basis, the total asset turnover ratio is structurally limited by the nature of the business, leaving room for improvement in capital efficiency.【Financial Soundness】The company has a solid financial foundation, with an Equity Ratio of 58.5%, a current ratio of 253.5%, and a quick ratio of 212.2%. Cash and deposits of ¥7.25B were 4.7 times short-term borrowings of ¥1.54B. Goodwill was ¥0.16B, equivalent to only 0.4% of net assets, indicating low dependence on M&A-related assets.

Cash Flow Analysis

Because detailed figures from the cash flow statement are not disclosed in this report, cash flow trends are analyzed based on changes in the balance sheet. Cash and deposits increased by ¥0.89B to ¥7.25B from ¥6.36B in the same period of the previous year. Inventories were ¥5.88B, up from ¥5.48B in the same period of the previous year, suggesting that inventory accumulation associated with revenue growth may be putting pressure on working capital. Accounts receivable and notes receivable were ¥8.49B, down from ¥9.80B in the same period of the previous year, indicating progress in collections. Property, plant and equipment was ¥20.79B, broadly unchanged, suggesting that large-scale investments were limited. Long-term borrowings remained at a level broadly in line with the ¥3.59B recorded in the same period of the previous year, with no significant change in financing through financial activities. Overall, cash generation commensurate with earnings growth can be confirmed, although the increase in inventory levels warrants attention from the perspective of working capital efficiency.

Quality of Earnings

Current-period earnings consisted solely of extraordinary income of ¥0.002B, with no extraordinary losses recorded, and can therefore be considered high quality because they were primarily generated by recurring operating profits. Non-operating income of ¥0.07B mainly consisted of dividend income of ¥0.02B and other income of ¥0.02B and does not represent a structure that materially supplements core operating profit. Corporate income taxes and other taxes of ¥0.40B were recorded against Profit Before Tax of ¥1.03B, resulting in a relatively high effective tax rate of approximately 38.3%, which constrained the conversion of pretax earnings into Net Income to a certain extent. Comprehensive income was ¥0.52B, below Net Income of ¥0.63B, with an adjustment related to retirement benefits of -¥0.11B being the primary difference. This divergence reflects temporary accounting fluctuations arising from the revaluation of pension assets and liabilities and should be noted as a divergence from Net Income, which reflects the company’s underlying earnings capacity.

Earnings Forecast and Guidance

The full-year company plan calls for revenue of ¥63.40B (+2.6% YoY), Operating Income of ¥4.60B (+6.1%), and Ordinary Income of ¥4.70B (+8.3%), with no revisions to either the earnings forecast or dividend forecast. Q1 progress rates were 23.6% for revenue, 21.5% for Operating Income, and 21.9% for Ordinary Income, slightly below the standard 25%. Q1 achieved earnings growth substantially exceeding revenue growth, and the key focus going forward will be whether this margin improvement can be maintained throughout the full year.

Shareholder Returns

The full-year dividend forecast remains unchanged at ¥42.0 per share, based on the level accumulated from the previous year’s actual annual dividend of approximately ¥17, including the interim dividend. Based on the full-year EPS forecast of ¥92.0, the Payout Ratio is approximately 45.7%, below the 60% level generally regarded as a benchmark for sustainability. Retained earnings of ¥36.64B and an Equity Ratio of 58.5% provide support for continued dividend payments. No share repurchase program is disclosed, and shareholder returns are evaluated solely on the basis of dividends.

Risk Factors

1. Deterioration in working capital efficiency: Inventories increased to ¥5.88B from ¥5.48B in the same period of the previous year, and both annualized inventory turnover days and the CCC tend to exceed benchmark levels. Attention is required regarding the risk of inventory write-downs and declining cash generation in the event of fluctuations in demand.

2. Concentration of earnings in the core segment: Medical Services accounts for approximately 71% of total reported segment profit. If institutional changes occur, such as revisions to the long-term care insurance system or reimbursement rates for welfare equipment rentals, the impact on company-wide performance could be significant.

3. Redemption and dilution risks related to equity-linked financial instruments: The company has recorded ¥5.03B in convertible bonds with stock acquisition rights and ¥1.50B in bonds. Although the interest burden is limited, with interest expense of ¥0.02B and interest coverage of 52.1 times, funding requirements at maturity and potential share dilution arising from conversion could affect the company’s future capital structure.

Industry Benchmark (Reference; Company Analysis)

Industry Benchmark (manufacturing)

Profitability and Returns

The company’s profitability is below the industry median for both indicators, placing it at a relatively low level in terms of margins.

Growth and Capital Efficiency

The revenue growth rate is also slightly below the industry median but remains within the IQR range and is not extremely inferior.

※Source: Company analysis

Key Points from the Earnings Results

1. In Q1, Revenue increased +4.2%, while Operating Income increased +26.6%, resulting in an improvement in the Operating Margin compared with the same period of the previous year. Earnings growth exceeding revenue growth reflects positive operating leverage from the absorption of SG&A expenses.

2. Interior Health’s segment profit increased substantially by +73.1% YoY. Whether this improvement can be sustained throughout the full year and its progress from Q2 onward will be key points of focus.

3. The increase in inventories and working capital efficiency indicators leave room for improvement relative to the industry average. Whether revenue and earnings growth can be converted into cash generation will be an important monitoring point.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,108–¥1,171 at ±1% for the cost of equity, and ¥1,137–¥1,140 at ±0.1 for ω.

Notes:

• Because forecast ROE is below the cost of equity, the theoretical value is below Book Value per Share.
• Net assets as of the end of the quarter are used; there is a timing difference relative to the full-year forecast.

(Calculation model: Residual Income Model (Ohlson type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was a strong start, with revenue growth translating into materially faster profit growth. Revenue increased 4.2% YoY to ¥14.97bn. Operating income rose 26.6% to ¥0.99bn. Ordinary income grew 30.0% to ¥1.03bn. Net income attributable to owners increased 33.0% to ¥0.63bn. Gross profit expanded 5.1% to ¥8.48bn, exceeding the rate of revenue growth. The gross margin improved by approximately 50bp YoY to 56.7%. SG&A rose only 2.8% YoY to ¥7.49bn, below revenue growth, producing favorable operating leverage. Consequently, the operating margin expanded by approximately 117bp to 6.6%. The net margin improved by approximately 92bp to 4.2%. Medical Service remained the core business by segment profit, generating ¥0.75bn, or about 71% of total segment profit before corporate adjustments. Interior Health was the principal earnings-growth driver, with segment profit up 73.1% YoY to ¥0.30bn. Q1 operating income represented 21.5% of the full-year plan, while revenue represented 23.6%, both broadly consistent with the normal 25% Q1 run-rate. Net income represented 20.7% of the ¥3.07bn full-year forecast, reflecting the relatively high 38.3% effective tax rate in Q1. The full-year forecast remains unchanged, calling for 2.6% revenue growth and 6.1% operating-income growth. Balance-sheet liquidity is robust, supported by a 253.5% current ratio and ¥16.26bn of cash and short-term investment securities. The central operational issue is working-capital efficiency, as elevated inventory-day and cash-conversion-cycle alerts point to capital being tied up in stock. Dividend affordability appears sound against the FY EPS and DPS forecasts, although sustained working-capital discipline remains important for cash returns.

Profitability Analysis

Annualized DuPont ROE is 6.4%, comprising a 4.2% net profit margin, 0.878x annualized asset turnover, and 1.71x financial leverage. The principal positive change in Q1 was margin expansion rather than balance-sheet leverage: operating margin improved to 6.6% from approximately 5.4% a year earlier, and net margin rose to 4.2% from approximately 3.3%. Gross margin improved by about 50bp to 56.7%, indicating a favorable revenue and cost mix. SG&A growth of 2.8% was below the 4.2% increase in sales, creating operating leverage and driving the 26.6% increase in operating income. The EBIT margin of 6.6% remains below the 8% level generally viewed as a strong profitability threshold, while annualized ROE of 6.4% remains below the 8% benchmark. The annualized ROA implied by net income and average assets is approximately 3.7%, indicating that the company’s profitability improvement has not yet translated into high asset productivity. Financial leverage is moderate rather than aggressive, and the 52.1x interest-coverage ratio indicates that financing costs are not constraining profitability. The tax burden ratio was 0.616, equivalent to a 38.3% effective tax rate, which restrained conversion of pre-tax profit into net income. Non-operating income was ¥0.07bn, only 0.4% of revenue, led by ¥0.03bn of interest income and ¥0.02bn of dividend income; it was not a material driver of earnings. Extraordinary income was limited to a ¥0.002bn gain on asset sales, so Q1 profit growth was predominantly operating in nature.

Growth Assessment

Revenue growth was broad-based across the two reportable segments. Medical Service revenue increased 3.3% YoY to ¥9.93bn, while segment profit increased 15.9% to ¥0.75bn; its segment margin improved to 7.5% from 6.7%. As the largest contributor to segment profit, Medical Service is the core business and provides the primary base for earnings stability. Interior Health revenue rose 5.9% to ¥4.90bn and segment profit advanced 73.1% to ¥0.30bn. Interior Health’s segment margin improved to 6.2% from 3.7%, making it the principal source of incremental profitability in the quarter. Other operations, including real-estate leasing, recorded external revenue of ¥0.15bn and segment profit of ¥0.01bn. Corporate and elimination costs improved to a ¥0.21bn loss from a ¥0.29bn loss, adding modestly to ordinary-income growth. The FY plan assumes revenue of ¥63.40bn, operating income of ¥4.60bn, ordinary income of ¥4.70bn, and net income of ¥3.07bn. Q1 progress versus plan is 23.6% for revenue, 21.5% for operating income, 21.9% for ordinary income, and 20.7% for net income. These are within 10 percentage points of the standard Q1 progress rate of 25%, so the quarter does not indicate a material departure from the annual plan. The unchanged forecast suggests management regards the Q1 margin gains as supportive but has not extrapolated them aggressively into the balance of the year.

Financial Health

Liquidity is strong. Current assets of ¥36.15bn exceeded current liabilities of ¥14.26bn by ¥21.89bn, producing working capital of ¥21.89bn and a current ratio of 253.5%. The quick ratio was also high at 212.2%, indicating that liquidity does not depend on inventory liquidation. Cash and deposits of ¥7.26bn plus short-term investment securities of ¥9.00bn totaled ¥16.26bn, exceeding short-term loans of ¥1.54bn by 10.6x. Current portions of long-term loans were ¥0.89bn, and cash plus short-term investment securities also comfortably cover these near-term loan maturities. Total interest-bearing debt was ¥5.13bn, consisting mainly of ¥3.59bn of long-term loans, ¥1.54bn of short-term loans, and ¥1.50bn of bonds payable. Reported debt-to-equity was 0.71x and debt-to-capital was 11.4%, both consistent with a conservative solvency profile. Interest coverage of 52.1x further supports a low refinancing-risk assessment. Convertible bonds with subscription rights totaled ¥5.03bn and are an important capital-structure consideration because they may create future dilution or refinancing requirements. Total equity was ¥39.88bn, while total liabilities were ¥28.28bn, resulting in a 58.5% capital adequacy ratio. Goodwill declined ¥0.58bn YoY, or 26.1%, to ¥0.16bn; given JGAAP goodwill amortization, this reduction is consistent with a limited and declining M&A-related carrying value rather than a material balance-sheet dependency. Goodwill represented only 0.4% of equity and 0.2% of total assets, leaving negligible goodwill-impairment exposure. PPE was ¥20.79bn, equal to 30.5% of assets, reflecting a meaningful but manageable fixed-asset base. Asset retirement obligations were ¥0.35bn, equal to approximately 1.2% of total liabilities, a contained level relative to the balance sheet.

Notable B/S Changes

Goodwill: -¥0.58bn YoY (-26.1%) to ¥0.16bn — consistent with a declining and immaterial JGAAP M&A-related asset base; goodwill is only 0.4% of equity, limiting impairment sensitivity. Finished goods: +¥0.40bn YoY (+7.3%) to ¥5.88bn — higher stock supports availability but is consistent with the elevated inventory-days alerts and warrants monitoring for turnover and obsolescence. Accounts receivable: -¥1.31bn YoY (-13.4%) to ¥8.49bn — lower trade receivables partly offset the working-capital burden from inventories. Cash and deposits: +¥0.90bn YoY (+14.2%) to ¥7.26bn — strengthens liquidity and coverage of short-term debt obligations. Provision for bonuses: -¥0.84bn YoY (-49.5%) to ¥0.86bn — reduces current liabilities and contributes to the improvement in the current ratio.

Cash Flow Quality

Q1 earnings quality is supported by the fact that operating-income growth was driven by gross-margin expansion and restrained SG&A growth, rather than by material non-operating or extraordinary gains. However, the working-capital profile requires close attention. One inventory-days alert indicates DIO of 123 days, materially above the 90-day warning level; the root cause is the sizable inventory position, including finished goods of ¥5.88bn, raw materials of ¥2.33bn, and work in process of ¥0.51bn. A separate inventory-days alert of 83 days also exceeds the 60-day manufacturing efficiency benchmark, reinforcing that inventory intensity is elevated under both flagged measurement approaches. For a bedding, healthcare-equipment, and interior-products business, stock availability can support service levels and delivery responsiveness, but persistently high days increase storage, obsolescence, markdown, and working-capital risks. The alert for a 144-day cash conversion cycle is also above the 120-day warning level; this indicates that the inventory holding period and customer collection cycle absorb cash for an extended period before supplier financing offsets it. Trade receivables were ¥8.49bn and electronically recorded monetary claims were ¥1.30bn, while trade payables and electronic obligations totaled ¥3.18bn. The investment implication is that continued profit growth should be accompanied by inventory normalization and disciplined receivables collection to protect cash conversion. Cash and deposits of ¥7.26bn, together with ¥9.00bn of short-term investment securities, provide a substantial liquidity buffer while management addresses working-capital efficiency.

Dividend Sustainability

The full-year dividend forecast is ¥42 per share, unchanged from the company’s forecast. Against forecast EPS of ¥92.0, the implied dividend payout ratio is approximately 45.7%. This is below the 60% sustainability benchmark and leaves room for retained earnings, investment, and balance-sheet flexibility. Q1 basic EPS was ¥19.02, up from ¥14.13 in the prior-year quarter, reflecting the 33.0% increase in net income. Retained earnings remained substantial at ¥36.64bn, equivalent to the overwhelming majority of total equity. The strong liquidity position and low debt-capital ratio support the company’s capacity to maintain the indicated dividend. Working-capital efficiency, particularly inventory intensity and the 144-day cash conversion-cycle alert, is the key operational factor to monitor in assessing ongoing cash-return capacity.

Risk Assessment

Business risks include Inventory risk: DIO alerts of 123 days and 83 days indicate elevated stock holding periods. This can be partly consistent with product availability needs in medical-care and interior businesses, but the impact is higher carrying costs, obsolescence exposure, and a potential need for discounting if sell-through slows., Cash-conversion risk: the 144-day cash conversion cycle exceeds the 120-day warning threshold. This suggests that inventory and receivables consume cash for a prolonged period, reducing the speed at which accounting earnings become deployable liquidity., Margin sustainability risk: Q1 operating-margin expansion depended on gross-margin improvement and SG&A growing more slowly than sales. Maintaining this outcome depends on continued pricing, procurement discipline, product mix, and volume growth., Industry-specific demand risk: Medical Service is the core earnings contributor, so changes in healthcare and nursing-care demand, reimbursement conditions, procurement practices, or service-provider utilization could affect growth and margins., Interior Health execution risk: segment profit grew 73.1% YoY and margin rose 250bp. The strong improvement raises the importance of sustaining favorable mix and cost control as the business scales..

Financial risks include Convertible-bond exposure: ¥5.03bn of convertible bonds with subscription rights may result in dilution or require refinancing, even though conventional debt-service capacity is strong., Tax-conversion risk: the 38.3% effective tax rate reduced net-income conversion, with a tax burden ratio of 0.616., Comprehensive-income volatility: comprehensive income of ¥0.52bn trailed net income of ¥0.63bn because other comprehensive income was negative ¥0.11bn, primarily reflecting pension remeasurement effects..

Key concerns include Highest priority: reduce inventory days and shorten the cash conversion cycle without compromising service levels., Monitor whether Q1 gross-margin and SG&A leverage gains can be sustained through the seasonally broader full-year revenue base., Track conversion and potential dilution terms associated with the ¥5.03bn convertible bond balance., Monitor progress against the unchanged full-year operating-income plan; Q1 progress of 21.5% is broadly normal but slightly below the 25% quarterly run-rate..

Investment Implications

Key takeaways include Q1 earnings momentum was strong: revenue rose 4.2%, while operating income and net income increased 26.6% and 33.0%, respectively., Profit growth was operationally driven, with gross margin up about 50bp and SG&A growth below sales growth., Medical Service is the core business by profit contribution, while Interior Health delivered the strongest incremental margin expansion., Liquidity and debt-service capacity are robust, with a 253.5% current ratio, 52.1x interest coverage, and 11.4% debt-to-capital., The primary operational constraint is working-capital efficiency, highlighted by elevated inventory days and a 144-day cash conversion cycle., The forecast dividend implies a 45.7% payout ratio based on FY EPS guidance, which appears balanced relative to earnings and capitalization..

Metrics to watch include Medical Service revenue growth and segment margin, Interior Health segment margin following the rise to 6.2%, Gross margin versus the Q1 level of 56.7%, SG&A growth relative to revenue growth, Inventory days under both flagged measures of 123 days and 83 days, Cash conversion cycle relative to the 144-day alert, FY operating-income progress versus the ¥4.60bn plan, Convertible-bond balance and any conversion-related developments, Effective tax rate and net-income conversion.

Regarding relative positioning, The company combines moderate profitability with a conservatively capitalized balance sheet. Its 6.6% operating margin and 6.4% annualized ROE are below higher-return benchmarks, but Q1 operating leverage, strong liquidity, low goodwill exposure, and high interest coverage provide resilience. Relative positioning will depend on whether management can convert the current margin improvement into durable returns while reducing the working-capital intensity signaled by the inventory and cash-conversion alerts.